Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NQO1 | P15559 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2323241 | 0.88 | KMT2A (0.54) | NCF1KMT2AMAPTNQO1ALDH1A1 | |
| SCHEMBL12957276 | 0.86 | NCF1 (0.54) | NCF1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL23452966 | 0.82 | NCF1 (0.74) | NCF1MAPTALDH1A1TP53CYP3A4 | |
| SCHEMBL20909590 | 0.80 | NCF1 (0.49) | NCF1ALDH1A1CYP1A2KDM4E | |
| SCHEMBL13737643 | 0.80 | MAPT (0.53) | NCF1KMT2AMAPTNQO1ALDH1A1 | |
| SCHEMBL622376 | 0.79 | ALDH1A1 (0.56) | NCF1KMT2ANQO1ALDH1A1HSD17B10 | |
| SCHEMBL20909360 | 0.79 | NCF1 (0.51) | NCF1ALDH1A1CYP3A4KDM4E | |
| SCHEMBL28158822 | 0.79 | CA12 (0.48) | NCF1KMT2AMAPTALDH1A1CA12 | |
| SCHEMBL29205379 | 0.79 | NCF1 (0.48) | NCF1ALDH1A1KDM4E | |
| SCHEMBL17430103 | 0.78 | ALDH1A1 (0.41) | NCF1KMT2AMAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531032-B1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | UNIV INDIANA RES & TECH CORP (US) | 2019-04-10 | — | — | EP | claimed |
| CN-105037266-A | Antibacterial chloroxoquinoline derivative | WANG ZIHOU | 2015-11-11 | — | — | CN | claimed |
| CN-105017145-A | Chloroxoquinoline derivative with anti-tumor activity | WANG ZIHOU | 2015-11-04 | — | — | CN | claimed |
| US-20140370121-A1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION | 2014-12-18 | — | — | US | claimed |
| US-8859532-B2 | Materials and method for inhibiting replication protein A and uses thereof | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) | 2014-10-14 | — | — | US | claimed |
| CN-103864681-A | Chloroxoquinoline derivatives for antibacterial use | WANG ZIHOU | 2014-06-18 | — | — | CN | claimed |
| CN-103864680-A | Chloroxoquinoline derivative with antineoplastic activity | WANG ZIHOU | 2014-06-18 | — | — | CN | claimed |
| US-20130028989-A1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-01-31 | — | — | US | claimed |
| EP-2531032-A1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | Indiana University Research and Technology Corporation (US) | 2012-12-12 | — | — | EP | claimed |
| WO-2011097545-A9 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORTION (US) | 2011-11-17 | — | — | WO | claimed |
| WO-2011097545-A1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORTION (US) | 2011-08-11 | — | — | WO | claimed |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2022-05-19 | — | — | US | disclosed |
| US-11208416-B2 | Selective inhibitors of protein arginine methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200361946-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRELUDE THERAPEUTICS INC (US) | 2020-11-19 | — | — | US | disclosed |
| EP-2531032-B1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | UNIV INDIANA RES & TECH CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-103588755-A | Preparation method for neratinib | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2014-02-19 | — | — | CN | disclosed |
| US-20130028989-A1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-01-31 | — | — | US | disclosed |
| EP-2531032-A1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | Indiana University Research and Technology Corporation (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097545-A9 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORTION (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011097545-A1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORTION (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140370121-A1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | RPA1, RPA3, PCNA | NCF1 1321/4885KMT2A 1671/4885MAPT 4175/4885 |
| US-20130028989-A1 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF | RPA1, RPA3, PCNA | NCF1 1321/4885KMT2A 1671/4885MAPT 4175/4885 |
| US-11208416-B2 | Selective inhibitors of protein arginine methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | NCF1 1771/4885KMT2A 409/4885MAPT 1824/4885 |
| US-20220153747-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | NCF1 1771/4885KMT2A 409/4885MAPT 1824/4885 |
| US-20200361946-A1 | Selective Inhibitors Of Protein Arginine Methytransterase 5 (PRMT5) | PRMT5, PRMT1, PRMT6 | NCF1 1771/4885KMT2A 409/4885MAPT 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.